ICM
TNDM icon

Invenomic Capital Management’s Tandem Diabetes Care TNDM Stock Holding History

Invenomic Capital Management’s Portfolio TNDM Stock Details TNDM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-241,006
Closed -$7.13M – 193
2023
Q4 		$7.13M Sell
241,006
-31,438
-12% -$652K 0.33% 88
2023
Q3 		$5.66M Buy
272,444
+190,273
+232% +$5.23M 0.24% 90
2023
Q2 		$2.02M Buy
+82,171
New +$2.64M 0.1% 116

Other funds holding TNDM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Invenomic Capital Management's TNDM Position: Q1 2024 in Review

Invenomic Capital Management sold out of Tandem Diabetes Care (TNDM) in Q1 2024, closing a stake of 241,006 shares — an estimated $7.13M sold.

Invenomic Capital Management first reported a position in TNDM in Q2 2023 and held it in 3 quarters. The position peaked at $7.13M in Q4 2023. 291 funds tracked by Wall St. Rank hold TNDM as of Q1 2024.

  • Invenomic Capital Management reported no remaining Tandem Diabetes Care position as of Q1 2024 after selling out during the quarter.
  • Invenomic Capital Management sold 241,006 Tandem Diabetes Care shares in Q1 2024, an estimated $7.13M.
  • Invenomic Capital Management first reported a position in Tandem Diabetes Care in Q2 2023 and held it in 3 quarters.
  • Invenomic Capital Management's Tandem Diabetes Care position peaked at $7.13M in Q4 2023.
  • 291 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q1 2024.

Based on Invenomic Capital Management's 13F filing for Q1 2024, filed 15 May 2024.